Serum Th1 and Th2 Profile Cytokine Level Changes in Patients with Graves' Ophthalmopathy Treated with Corticosteroids

The aim of this study was to estimate the influence of corticosteroids on Th1 and Th2 serum cytokine balance in patients with GO: IFNγ, TNFα, IL-4 and IL-10. Further, we tested the hypothesis of an up-regulation of Th2 immune response during successful treatment with corticosteroids to explain their beneficial effect in Graves' ophthalmopathy. Serum cytokines were detected in three groups of subjects: 20 patients with Graves' disease without ophthalmopathy (Gd), 16 patients with clinical symptoms of ophthalmopathy (GO) (CAS over 3 points, last consultation record for GO less than a year old) and 16 healthy volunteers. Corticosteroid therapy consisted of intravenous infusions of methylprednisolone (MP) (2 series, 3 g each time) and subsequent treatment with oral prednisone (60 mg per day) in a tapering schedule. The serum samples were collected 24 hours before MP, 24 hours after MP, 14 days of treatment with prednisone and at the end of corticosteroid therapy. The levels of IFNγ, TNFα, IL-4 and IL-10 in the serum were determined using ELISA. Statistical significance was estimated by the Mann-Whitney U-test. Our findings show a deviation to systemic Th2 profile cytokines in Graves' disease. In patients with GO, we found a significantly increased serum IL-10 concentration. In corticosteroid-responsive patients, the balance of serum cytokines IL-4/IFNγ, IL-4/TNFα, IL-10/IFNγ and IL-10/TNFα increased and remained upregulated until the end of the study. In non-responders, the balance of serum cytokines studied increased after methylprednisolone but declined markedly during continuation of the therapy with prednisone. In summary, our results show that efficient corticosteroid therapy may be related to its influence on Th2/Th1 profile cytokine balance. The upregulation of serum IL-4 and IL-10 during successful treatment with corticosteroids indicate the possibility of using these cytokines as predictors of the beneficial effect of corticosteroids in Graves' ophthalmopathy.

Key words:

Graves' Disease - Ophthalmopathy - Cytokines - Th1/Th2 Balance - Corticosteroids

References

• 1 Natt N, Bahn R S. Cytokines in the evolution of Graves' ophthalmopathy.  Autoimmunity. 1997;  26 129-136
• 2 Mossman T R, Cherwinski H, Bond M W, Giedlin M A, Coffman R L. Two types of murine helper T cell clone. Definition according to profiles of lyphokine activities and secreted proteins.  J Immunol. 1986;  123 2348-2357
• 3 de Carli M, D'Elios M, Maritti S, Marcocci C, Pinchera A, Ricci M. Cytolytic T cells with TH-1 like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy.  J Clin Endocrinol Metab. 1993;  77 1120-1124
• 4 Grubeck-Loebenstein B, Trieb K, Sztankay A, Holter W, Anderl H, Wick G. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts.  J Clin Invest. 1994;  3 2738-2743
• 5 Heufelder A E, Bahn R S. Detection and localization of cytokine immunoreactivity in retroocular connective tissue in Graves' ophthalmopathy.  Eur J Clin Invest. 1993;  23 10-17
• 6 Heufelder A E, Bahn R S. Modulation of Graves, orbital fibroblast proliferation by cytokines and corticosteroid receptor agonists.  Invest Ophthalmol Vis Sci. 1994;  35 120-127
• 7 Kazim M, Trokel S, Moore S. Treatment of acute Graves' orbitopathy.  Ophthalmology. 1991;  98 1443-1448
• 8 Nagayama Y, Izumi M, Kiriyama T. Treatment of Graves' ophthalmopathy with high-dose intravenous metylprednisolone pulse therapy.  Acta Endocrinologica (Copenh). 1987;  116 513-518
• 9 Guy J R, Fagien B, Donovan J, Rubin M L. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy.  Ophthalmology. 1989;  96 1048-1053
• 10 Mourits M, Koorneef L, Wiersinga W M, Prummel M F, Berghout A, Gaag R D. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.  Brit J Ophthalmol. 1989;  73 639-644
• 11 Moore K W, O'Garra A, Malefyt D W, Viera P, Mossman T R. Interleukin 10.  Ann Rev Immunol. 1993;  11 165-190
• 12 de Waal Malefyt R, Haanen J, Spits H, Roncarolo M G, te Velde A, FiGdor C, Johnson K, Kastelein R, Yssel H, de Vries J E. Interleukin 10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation class II major histocompatibility complex expression.  J Exp Med. 1991;  174 915-1001
• 13 Koppelman B, Neefjes J J, de Vriesand R, DeWaal Malefyt R. Interleukin-10 down-regulates MHC class IIαβ peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling.  Immunity. 1997;  7 861-866
• 14 Willems F, Marchant J P, Delville C, Gerard A, Delvaux T, Velu T, de Boer M, Goldman M. Interleukin 10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes.  Eur J Immunol. 1994;  24 1007-1010
• 15 de Waal Malefyt R, Abrams J, Benett B, FiGdor C G, de Vries J E. Interleukin 10 inhibits cytokines synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.  J Exp Med. 1991;  174 1209-1215
• 16 Fiorentino D F, Zlotnik A, Mossman T R, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages.  J Immunol. 1991;  147 3815-3821
• 17 Dandona P, Aljada A, Garg R, Mohanty P. Increase in plasma interleukin-10 following hydrocortisone injection.  J Clin Endocrinol Metab. 1999;  84 1141-1144
• 18 Kalmann B A, Hurter M, Tubes M, Feldkamp J, Bertrams J, Gries FA, Lampeter E F, Kolb H. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease.  Diabetes. 1997;  46 237-243
• 19 Heufelder A E, Bahn R S. Elevated expression in situ of selectin and immunoglibulin superfamily adhesion molecules in retroocular connective tissues from patients with Graves' Ophthalmopathy.  Clin Exp Immunol. 1993;  91 381-389
• 20 Weetman A P, Cohen S, Gatter K C, Fells D, Shine B. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy.  Clin Exp Immunol. 1989;  75 222-227
• 21 Bahn R, Heufelder A E. Mechanisms of disease: pathogenesis of Graves' ophthalmopathy.  N Engl J Med. 1993;  329 1468-1475
• 22 Bahn R, Heufelder A E. Role of connective tissue autoimmunity in Graves' ophthalmopathy.  Autoimmunity. 1992;  13 75-79
• 23 Leonardi A, Borghesan F, DePaoli M, Plebani M, Secchi A G. Procollagens and inflammatory cytokine concentrations in tarsal and limbal vernal keratoconjunctivitis.  Exp Eye Res. 1998;  67 105-112
• 24 Pleyer U, Milani J K, Ruckert D, Rieck P, Mondino B J. Determinations of serum tumor necrosis factor alpha in corneal allografts.  Ocul Immunol Inflamm. 1997;  5 149-155
• 25 Slepova O S, Gerasimenko V A, Makarov V P, Kushnir V N. Comparative study of the role of cytokines in different forms of eye diseases.  Vestn Oftalmol. 1998;  114 28-32
• 26 Barnes P J. Antiinflammatory actions of corticosteroids: molecular mechanisms.  Clin Sci. 1998;  84 557-572
• 27 Heufelder A E, Bahn R S, Smith T J. Regulation by corticosteroids of interferon gamma-induced HLA-DR antigen expression in cultured human orbital fibroblasts.  Clin Endocrinol. 1992;  37 659-643
• 28 Abbas A K, Murphy K M, Sher A. Functional diversity of helper T lymphocytes.  Nature. 1996;  383 787-793